Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects.

ABSTRACT: Bioenergetics and bioenergetic-related functions are altered in Alzheimer's disease (AD) subjects. These alterations represent therapeutic targets and provide an underlying rationale for modifying brain bioenergetics in AD-affected persons. Preclinical studies in cultured cells and mice found that administering oxaloacetate (OAA), a Krebs cycle and gluconeogenesis intermediate, enhanced bioenergetic fluxes and upregulated some brain bioenergetic infrastructure-related parameters. We therefore conducted a study to provide initial data on the tolerability and pharmacokinetics of OAA in AD subjects. Six AD subjects received OAA 100 mg capsules twice a day for one month. The intervention was well-tolerated. Blood level measurements following ingestion of a 100 mg OAA capsule showed modest incr

SUBMITTER: Swerdlow RH 

PROVIDER: S-EPMC4816034 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature